Gufic Biosciences has informed that the Board of Directors of the Company at its Meeting held on June 04, 2021 considered and approved the allotment of 1,91,14,506 Equity Shares of the Company of FV of Re 1 each to the Shareholders of Gufic Lifesciences ('Transferor Company' or 'GLPL') pursuant to the Scheme of Amalgamation of Gufic Lifesciences ('Transferor Company') with the Company ('Transferee Company') and their shareholders and creditors; the Audited Financial Results for the quarter and financial year ended March 31, 2021; and recommended Dividend at 10% i.e. Re 0.10 per equity share (Face Value of Re 1 each) for the financial year ended March 31, 2021, subject to the approval of the Shareholders at the ensuing Annual General Meeting.
The above information is a part of company’s filings submitted to BSE.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: